Company / SG&A Expense
AbbVie SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$14.0B
FY2025
5-year range
$12.3B / $15.3B
FY2021-FY2025
Trend
-5.0%
vs FY2024
Sector context
#2 of 211
Health Care
What the data says
Among 211 Health Care companies, AbbVie is in the bottom 1% for sg&a expense. SG&A Expense has fluctuated over the past 10 years, ranging from $5.9B in FY2016 to $15.3B in FY2022.
Based on SEC 10-K filings.
$14.0B in FY2025 with a 5-year CAGR of +4.4%. Ranks 2nd among 211 companies in Health Care.
Increased from $12.9B to $14.0B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -2.8%
- 5-Year CAGR
- +4.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 211This company $14.0B Sector average $728.7M
▼
+1822.6% above sector average
Key checks
Key Insights
- 5-year CAGR of +4.4%, indicating consistent growth.
- In FY2025, sg&a expense decreased 5.0% year-over-year.
- Ranks #2 out of 211 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $14.0B | -5.0% |
| FY2024 | $14.8B | +14.6% |
| FY2023 | $12.9B | -15.6% |
| FY2022 | $15.3B | +23.6% |
| FY2021 | $12.3B | +9.3% |
| FY2020 | $11.3B | +62.8% |
| FY2019 | $6.9B | -6.2% |
| FY2018 | $7.4B | +17.5% |
| FY2017 | $6.3B | +7.0% |
| FY2016 | $5.9B | -7.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026